.
BioEnterprise

Visum Therapeutics

Visum Therapeutics is developing a small molecule therapeutic to treat Stargardt’s disease, a degenerative condition that leads to blindness and is the most common form of inherited juvenile macular degeneration.

Stage

Preclinical